BioNTech Burns Through €532 Million as Factory Closures and Founder Departure Mark End of COVID Era

BioNTech posts €531.9M Q1 loss on collapsing COVID revenue, but activates $1B buyback and invests €557M in oncology pivot amid founder exit and factory closures.

The numbers tell a brutal story of transition. BioNTech posted a net loss of €531.9 million in the first quarter of 2026, as revenue collapsed to just €118.1 million from €182.8 million a year earlier. Yet the Mainz-based biotech is simultaneously activating a $1 billion share buyback and sitting on a cash hoard of €16.8 billion — one of the largest war chests in the biopharma sector.

The apparent contradiction dissolves on closer inspection. BioNTech is spending heavily to reinvent itself, pouring €557 million into research and development during the quarter, with the bulk directed at oncology candidates Pumitamig and Gotistobart, plus costs from the 2025 acquisitions of BioNTech China and CureVac. The adjusted loss per share of €1.95 actually beat analyst expectations of $2.27, offering a sliver of comfort to investors watching the stock slide.

A Factory Shutdown and a Founder Exodus

The restructuring is sweeping. BioNTech has eliminated 1,860 manufacturing jobs and will close four sites — in Idar-Oberstein, Marburg, Tübingen and Singapore — by the end of 2027. The closures are expected to save €500 million annually. But the most dramatic change comes at the top: founders Ugur Sahin and Özlem Türeci will leave the company at year-end to launch a new venture focused on mRNA technologies, severing their final ties with the business they built from a small Mainz lab into a pandemic-era titan.

The boardroom upheaval coincides with a strategic pivot that could define BioNTech's next decade. The company launched five Phase 3 trials for Pumitamig in a single quarter, targeting aggressive cancers including triple-negative breast cancer. It is also testing combination therapies in partnership with Boehringer Ingelheim, with initial data expected later this year.

Buyback as a Confidence Signal

The $1 billion ADS repurchase program, formally activated Thursday and running until May 6, 2027, is designed to support the stock through this turbulent transition. Shares are currently trading around €81, roughly 22% below their 52-week high and well under the 50-day moving average, having lost more than 10% in the past seven days alone.

Management is standing by its full-year guidance: revenue between €2.0 billion and €2.3 billion, with adjusted R&D spending of €2.2 billion to €2.5 billion. As in 2025, the bulk of sales is expected to arrive in the final four months, reflecting the seasonal nature of COVID vaccine demand that continues to fade.

The ASCO Moment

The next major catalyst arrives in late May at the ASCO congress, where BioNTech will present Phase 2 data from the ROSETTA Lung-02 study of Pumitamig. A positive readout could provide the first concrete evidence that the oncology pivot can fill the gap left by shrinking COVID revenues. Pfizer and BioNTech recently halted a large US trial of their updated COVID vaccine for adults aged 50 to 64 due to insufficient enrollment — not safety concerns — underscoring how quickly pandemic-era demand has evaporated.

The market is waiting for proof, not promises. With €16.8 billion in cash, BioNTech has the runway to execute its transformation. Whether the pipeline delivers before that cash burns down is the question that will determine whether this is a strategic reinvention or a costly gamble.